Abstract
High-dose multi-agent chemotherapy with autologous hematopoietic stem cell transplantation is applied in the treatment of children and young adults with brain tumors and different risk factors for poor prognosis. Thereby myeloablative chemotherapy is administered in high - risk patients ' group after initial surgery and standard-dose chemotherapy. The success of high-dose chemotherapy depends on the histological type of tumor, extent of disease, extent of surgical resection, and response to prior chemotherapy. This review presents results of myeloablative multi-agent chemotherapy with autologous hematopoietic stem cell transplantation in brain tumors of different histologic types and modern strategies in pediatric central nervous system tumors treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have